Riedel Richard F, Crawford Jeffrey
Division of Medical Oncology and Transplantation, Herman and Ruth Albert Thoracic Oncology Program, Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, NC 27710, USA.
Semin Thorac Cardiovasc Surg. 2003 Oct;15(4):448-56. doi: 10.1053/s1043-0679(03)00098-4.
Small-cell lung cancer (SCLC) is expected to account for 25% of the approximate 170,000 cases of lung cancer diagnosed in the United States in 2002. Although sensitive and responsive to chemotherapy, SCLC has an increased propensity for early metastases, with relapses being common and long-term survival rates being poor. Clinical trials have played a vital role in expanding our knowledge base for this disease and have resulted in newer modalities, including chemotherapeutic agents, prophylactic cranial irradiation, and thoracic radiotherapy designed to improve overall outcomes. Clinical trials have also served to clarify the role of surgery in a disease that traditionally has been thought to be nonoperable. This review will focus on the results of clinical trials that have had an effect on the treatments of patients with limited and extensive-stage SCLC, with recommendations from the National Comprehensive Cancer Network being emphasized.
2002年，在美国确诊的约17万例肺癌病例中，预计小细胞肺癌（SCLC）占25%。尽管小细胞肺癌对化疗敏感且有反应，但它早期转移的倾向增加，复发常见，长期生存率低。临床试验在拓展我们对该疾病的知识库方面发挥了至关重要的作用，并带来了更新的治疗方式，包括化疗药物、预防性颅脑照射和胸部放疗，旨在改善总体治疗效果。临床试验还有助于明确手术在这种传统上被认为不可手术的疾病中的作用。本综述将重点关注对局限期和广泛期小细胞肺癌患者治疗产生影响的临床试验结果，并强调美国国立综合癌症网络的建议。
